Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Insight into the mechanism of laquinimod action.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Interferon-β-1b: a review of its use in multiple sclerosis.
β-Amyloid: Enemy or Remedy?
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Chemical and Biological Therapeutic Approaches to Neurological Disorders III
NOVANTRONE. mitoXANTRONE for injection concentrate
Molecular characterization of a peripheral receptor for cannabinoids.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review

Pages